Stryker’s OptaBlate® Basivertebral Nerve Ablation (BVN) System, recently granted 510(k) clearance by the U.S. Food and Drug Administration (FDA), marks a major advancement in the treatment of chronic vertebrogenic low back pain. Designed with precision-focused radiofrequency ablation technology, the system includes a steerable curved introducer, microinfusion to reduce charring and impedance errors, and a fast lesioning capability that creates a 1 cm ablation in just seven minutes. These innovations streamline the procedure and enhance safety, enabling physicians to deliver consistent, controlled results with minimal tissue disruption.

This minimally invasive system is particularly significant for patients with chronic low back pain linked to Modic type 1 or 2 changes—an often underdiagnosed and undertreated subset. Traditional conservative therapies like physical therapy, injections, or medication frequently fall short of providing lasting relief. OptaBlate BVN directly targets the basivertebral nerve, which transmits pain signals from damaged vertebral endplates. By ablating this nerve, the system offers a durable, non-surgical solution that can significantly improve patient outcomes and potentially delay or eliminate the need for more invasive interventions.

With its FDA clearance, OptaBlate BVN strengthens Stryker’s position in the interventional spine and pain management markets, aligning with the company’s strategy to expand access to advanced, non-opioid treatment options. As back pain remains one of the leading causes of disability in the United States and worldwide, this technology provides clinicians with a critical new tool to treat an underserved patient population. Stryker’s continued focus on innovation reinforces its commitment to improving quality of life through smarter, safer, and more effective therapies.

MedTech Spectrum's Summary

Targeted, Lasting Pain Relief: OptaBlate BVN directly ablates the basivertebral nerve—addressing the root cause of vertebrogenic low back pain in patients with Modic changes—offering a durable alternative to medications or surgery.

Innovative Technology: The system features a steerable introducer, microinfusion to prevent charring, and fast lesioning capability (1 cm in 7 minutes), enhancing precision, safety, and procedural efficiency.

Expands Non-Opioid Pain Solutions: As part of Stryker’s advanced pain portfolio, OptaBlate BVN fills a critical gap in minimally invasive spine care, supporting the shift toward non-opioid, outpatient-based interventions.